Other Clinical Trial - Prasterone (DHEA) for the Treatment of Hypoactive

See also
Status	Clinical Trial	Phase
Completed	`NCT03080298` - Study of the Efficacy and Safety of BP101 in Female Patients With Decrease or Loss of Sexual Desire	Phase 2
Completed	`NCT00349791` - Study to Assess the Efficacy/Safety of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido	Phase 3
Completed	`NCT02070029` - Acupuncture for Sexual Dysfunction	N/A
Completed	`NCT01702818` - Stress Hormones, Mood and Women's Sexual Desire (MODEST)

See also

Status

Clinical Trial

Phase

Completed

NCT03080298 - Study of the Efficacy and Safety of BP101 in Female Patients With Decrease or Loss of Sexual Desire

Phase 2

Completed

NCT00349791 - Study to Assess the Efficacy/Safety of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido

Phase 3

Completed

NCT02070029 - Acupuncture for Sexual Dysfunction

N/A

Completed

NCT01702818 - Stress Hormones, Mood and Women's Sexual Desire (MODEST)

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT03619005
Study type	Interventional
Source	EndoCeutics Inc.
Contact
Status	Withdrawn
Phase	Phase 3
Start date	November 13, 2018
Completion date	December 6, 2019

Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - Second Study

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms